Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has established affiliates in Brazil and Mexico, the two largest pharmaceutical markets in Latin America1, as first steps in its expansion outside of Europe. As part of the expansion into Brazil, Neuraxpharm has… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial… Read More
This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “… Read More
This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “… Read More
The Summer 2023 issue of Drug Discovery World Magazine is out now and includes an exclusive guide on Therapeutic Antibodies. Featuring a Therapeutic Spotlight on Immuno-oncology, the magazine is available to download free here and read for free on the DDW App. You can also… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have heard about a number of studies that demonstrate an inventive… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have heard about a number of studies that demonstrate an inventive solution to… Read More
Cytiva and BioCentriq, a new Jersey-based cell and gene therapy contract development and manufacturing organisation (CDMO), have been awarded funding from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public-private partnership whose mission is to accelerate biopharmaceutical innovation. Viral clearance is a key regulatory requirement… Read More
From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London. DDW’s Megan Thomas shares highlights from the event programmes. Programmes This year’s summit was made up of conference programmes, which included: Modulating the Tumour Microenvironment; Next-Generation Cell-Based Immunotherapies; Bispecific and Multi-Specific Antibody Therapeutics, and… Read More
Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, has announced a breakthrough in its influenza AI Programme with CytoReason. Poolbeg has been working with CytoReason since March 2022. Poolbeg’s disease progression data from influenza human challenge… Read More
This is the latest episode of the free DDW narrated podcast, “Reaching new heights with drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “High-throughput technologies: Reaching for the stars” and “… Read More
This is the latest episode of the free DDW narrated podcast, “Reaching new heights with drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “High-throughput technologies: Reaching for the stars” and “A different future is… Read More
Verona Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ensifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and non-steroidal… Read More
MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has completed enrolment and initial dosing in its Phase I clinical vaccine trial in older adults. The trial is taking place at CEVAC (Centre for Vaccinology), Ghent University, Belgium. GBS is most… Read More
The Commonwealth Government’s Medical Research Future Fund (MRFF) has invested $9.75 million into establishing MedChem Australia, a new national medicinal chemistry initiative. MedChem Australia will bring together three medical chemistry groups in Australia from the University of Sydney, Monash University and the Walter and Eliza Hall Institute… Read More
